Jose Vieira - Procaps Group Chief Officer
| PROC Stock | USD 0.92 0.19 17.12% |
Executive
Jose Vieira is Chief Officer of Procaps Group SA
| Age | 58 |
| Address | 9 Rue de Bitbourg, Luxembourg, Luxembourg, 1273 |
| Phone | 356 7995 6138 |
| Web | https://www.procapsgroup.com |
Procaps Group Management Efficiency
The company has return on total asset (ROA) of 0.0628 % which means that it generated a profit of $0.0628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3737 %, meaning that it created $0.3737 on every $100 dollars invested by stockholders. Procaps Group's management efficiency ratios could be used to measure how well Procaps Group manages its routine affairs as well as how well it operates its assets and liabilities. At present, Procaps Group's Return On Assets are projected to increase slightly based on the last few years of reporting. At present, Procaps Group's Intangibles To Total Assets are projected to increase slightly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.99, whereas Total Assets are forecasted to decline to about 445.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Glenn David | Phibro Animal Health | 52 | |
| Ori Gutwerg | ANI Pharmaceuticals | 49 | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Krista Davis | ANI Pharmaceuticals | 50 | |
| James Marken | ANI Pharmaceuticals | 61 | |
| Christine CPA | Prestige Brand Holdings | 48 | |
| Mary MD | ANI Pharmaceuticals | N/A | |
| Chad Gassert | ANI Pharmaceuticals | 48 | |
| Thomas Rowland | ANI Pharmaceuticals | 57 | |
| Richard Johnson | Phibro Animal Health | 75 | |
| Christopher Mutz | ANI Pharmaceuticals | 53 | |
| Mary Fritz | Prestige Brand Holdings | N/A | |
| MD FAAFP | Collegium Pharmaceutical | 63 | |
| Larry Miller | Phibro Animal Health | 60 | |
| YatPui Au | Regencell Bioscience Holdings | 50 | |
| Antonia Assang | Regencell Bioscience Holdings | N/A | |
| Tien Chau | Regencell Bioscience Holdings | 54 | |
Management Performance
| Return On Equity | 0.37 | ||||
| Return On Asset | 0.0628 |
Procaps Group SA Leadership Team
Elected by the shareholders, the Procaps Group's board of directors comprises two types of representatives: Procaps Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Procaps. The board's role is to monitor Procaps Group's management team and ensure that shareholders' interests are well served. Procaps Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Procaps Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Camilo Camacho, Chief Officer | ||
| Marcela Pagano, VicePresident Affairs | ||
| Ruben Minski, Founder Chairman | ||
| Carlos Russo, Head Finance | ||
| Luis Aragon, VicePresident RD | ||
| Jose Vieira, Chief Officer | ||
| Mauricio Caballero, VicePresident Resources | ||
| Melissa Angelini, Investor Director | ||
| Patricio Munoz, Global Officer |
Procaps Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Procaps Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.37 | ||||
| Return On Asset | 0.0628 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 367.89 M | ||||
| Shares Outstanding | 112.82 M | ||||
| Shares Owned By Insiders | 83.02 % | ||||
| Shares Owned By Institutions | 2.81 % | ||||
| Number Of Shares Shorted | 20.49 K | ||||
| Price To Book | 2.64 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Procaps Group SA is a strong investment it is important to analyze Procaps Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Procaps Group's future performance. For an informed investment choice regarding Procaps Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Procaps Group SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Procaps Group. If investors know Procaps will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Procaps Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.64) | Earnings Share 0.51 | Revenue Per Share 4.097 | Quarterly Revenue Growth 0.073 | Return On Assets 0.0628 |
The market value of Procaps Group SA is measured differently than its book value, which is the value of Procaps that is recorded on the company's balance sheet. Investors also form their own opinion of Procaps Group's value that differs from its market value or its book value, called intrinsic value, which is Procaps Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Procaps Group's market value can be influenced by many factors that don't directly affect Procaps Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Procaps Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Procaps Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Procaps Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.